ADSB-FUB-187
ADSB-FUB-187 is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.09 nM and an EC50 of 1.09 nM.[1] It was originally developed by Pfizer in 2009, being example 187 from patent WO 2009/106982. While it is the most tightly binding compound from this patent in terms of Ki, it is not the most potent compound at producing a CB1 mediated pharmacological effect, with at least 17 other compounds from the patent having lower EC50 values.[2]
Legal status | |
---|---|
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C26H31ClFN5O4S |
Molar mass | 564.07 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Legality
Sweden's public health agency suggested classifying ADSB-FUB-187 as hazardous substance on November 10, 2014, following its use as an ingredient in grey-market synthetic cannabis products.[3]
References
- Banister SD, Connor M (2018). "The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution". Handbook of Experimental Pharmacology. 252: 191–226. doi:10.1007/164_2018_144. PMID 30105473.
- WO 2009106982, Buchler IP, Hayes MJ, Hedge SG, Landis S, Hockerman SL, Jones DE, Kortum SW, Rico JG, Tenbrink RE, Wu KW, "Indazole derivatives", published 3 September 2009, assigned to Pfizer Inc..
- "Cannabinoider föreslås bli klassade som hälsofarlig vara" [Cannabinoids are proposed to be classified as hazardous to health] (in Swedish). Folkhälsomyndigheten (The Swedish Public Health Agency). Archived from the original on 25 March 2015. Retrieved 8 July 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.